Atara Biotherapeutics (ATRA) Sees Large Volume Increase

Atara Biotherapeutics Inc (NASDAQ:ATRA) shares saw unusually-strong trading volume on Monday . Approximately 3,694,300 shares traded hands during trading, an increase of 159% from the previous session’s volume of 1,425,811 shares.The stock last traded at $28.25 and had previously closed at $22.15.

A number of analysts have recently commented on ATRA shares. Canaccord Genuity restated a “buy” rating on shares of Atara Biotherapeutics in a report on Thursday, November 9th. Jefferies Group restated a “buy” rating and set a $30.00 price objective on shares of Atara Biotherapeutics in a report on Thursday, October 5th. Citigroup upgraded Atara Biotherapeutics from a “sell” rating to a “neutral” rating and set a $18.00 price objective for the company in a report on Wednesday, January 3rd. Goldman Sachs Group restated a “neutral” rating and set a $20.00 price objective on shares of Atara Biotherapeutics in a report on Friday, October 6th. Finally, ValuEngine upgraded Atara Biotherapeutics from a “sell” rating to a “hold” rating in a report on Friday, December 29th. Four equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $26.00.

The stock has a market capitalization of $864.33, a PE ratio of -8.14 and a beta of 1.27.

Atara Biotherapeutics (NASDAQ:ATRA) last announced its quarterly earnings results on Thursday, November 9th. The biotechnology company reported ($1.02) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.05). sell-side analysts expect that Atara Biotherapeutics Inc will post -4 EPS for the current fiscal year.

In other Atara Biotherapeutics news, CFO John Mcgrath sold 32,000 shares of the company’s stock in a transaction dated Friday, December 29th. The shares were sold at an average price of $20.00, for a total value of $640,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Gad Soffer sold 7,000 shares of the company’s stock in a transaction dated Friday, November 17th. The shares were sold at an average price of $15.00, for a total transaction of $105,000.00. Following the completion of the transaction, the executive vice president now directly owns 166,342 shares of the company’s stock, valued at $2,495,130. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 190,088 shares of company stock valued at $3,795,591. 16.20% of the stock is owned by corporate insiders.

A number of large investors have recently bought and sold shares of the business. Neuberger Berman Group LLC boosted its position in Atara Biotherapeutics by 15.2% in the 3rd quarter. Neuberger Berman Group LLC now owns 1,115,041 shares of the biotechnology company’s stock valued at $18,454,000 after buying an additional 147,061 shares during the last quarter. Vanguard Group Inc. boosted its position in Atara Biotherapeutics by 1.7% in the 2nd quarter. Vanguard Group Inc. now owns 845,877 shares of the biotechnology company’s stock valued at $11,842,000 after buying an additional 13,952 shares during the last quarter. Artal Group S.A. boosted its position in Atara Biotherapeutics by 20.0% in the 3rd quarter. Artal Group S.A. now owns 600,000 shares of the biotechnology company’s stock valued at $9,930,000 after buying an additional 100,000 shares during the last quarter. Northern Trust Corp boosted its position in Atara Biotherapeutics by 12.0% in the 2nd quarter. Northern Trust Corp now owns 298,739 shares of the biotechnology company’s stock valued at $4,183,000 after buying an additional 32,065 shares during the last quarter. Finally, Bank of New York Mellon Corp boosted its position in Atara Biotherapeutics by 4.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 125,713 shares of the biotechnology company’s stock valued at $1,760,000 after buying an additional 5,616 shares during the last quarter. 69.67% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION WARNING: This news story was posted by Transcript Daily and is the sole property of of Transcript Daily. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The correct version of this news story can be read at https://transcriptdaily.com/2018/01/15/atara-biotherapeutics-atra-sees-large-volume-increase.html.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply